AVI releases DMD drug Phase 1b/2 trial results
The results of the trial suggested that the drug was well tolerated and improved dystrophin expression in patients. The 19-patient, 12-week, six dose cohort study investigated the safety,
Harbour BioMed’s partner Solstice Oncology has raised $225m in funding to advance its lead candidate, porustobart, a neoadjuvant immuno-oncology therapy.